Relay races toward pivotal trial as breast cancer data tee up clash with AstraZeneca's Truqap

Relay Therapeutics has beaten its survival goal in a first-in-human breast cancer study, positioning the biotech to move into a pivotal trial that could establish its candidate as a challenger to AstraZeneca’s Truqap.